GARDASIL…… SAFE,……..uuhhh, except for the 32 reported deaths.

But hey gotta’ do it to them,……for their future sexual activity.  What an evil ploy.  Force potentially dangerous chemicals into the little bodies of our children.  Make us pay for this very suspect ‘preventative’.  And what is the huge message given to these little kids?  Why OF COURSE you will be “sexually active” in no time at all.  So just roll up the sleeve now.

Through lobbying efforts, Merck has suggested that governments make vaccination with Gardasil mandatory for school attendance

How vile and perverse and disgusting.  How low will pharmaceuticals  stoop to maintain their billion-dollar empires?  Leave the children alone!  Let them climb trees and play with their friends and learn about life from parents and loved ones.  Children are so easily influenced.  WHY would we want to predispose them to think it inevitable that they are just going to be allowing their bodies to become nothing more than pieces of meat to gratify the sexual urges of the world around them.

We are not mere bone-head cave dwellers, lurching about looking to satisfy nothing more than a need for food and sex.  We have been made in the image of almighty God.  We are capable of incredible creativity, artistry, intelligence, altruism.  God calls us to sexual purity, to faithfulness in marriage.  YOU, Gregory Poland, and your employer Merck seek to undermine the development of children by implying they cannot and will not become masters of their sexuality.  All must grovel in the cesspool of sex everywhere, anytime, no self-control or higher moral values in sight.

Parents, do not allow this degradation and perhaps even directly harmful injection to be given to your precious little children, on the assumption that they will not have the moral strength to withstand the pressures of a fallen world.  Your kids are most precious in the eyes of God.  Loose morals never make for exalted living.

I’ve spent many years volunteering and say unwaveringly that giving, or having their purity taken from them early in life, sets young people on an unnecessarily painful and difficult journey through life.  And God says it would be preferable to have a mill-stone tied around your neck and be cast into the sea, than to cause one of His little ones to sin.

Do not allow the state to inject your child with Gardasil.  Fill your child’s life with love and laughter and self-confidence and good friends and give them skills.  Read good literature to them.  Tell them about God, who alone can fill their lives with ultimate meaning.

(Below are some excerpts from Blackwell’s article.  The bold and red highlights are mine.  – Gerda)

Tom Blackwell | March 8, 2016 | 

A Canadian co-authored study critical of the human papillomavirus vaccine (HPV) has now been permanently spiked by a prestigious medical journal, with one outside expert suggesting it contained numerous “gross errors.”

The small animal study had actually been accepted by Vaccine and published online, then pulled temporarily last month by the editor, who had it peer-reviewed a second time — an unusual sequence of events.

The paper concluded that mice injected with the Gardasil HPV vaccine exhibited behavioural abnormalities and suggested putting a curb on mass programs to immunize girls against the cancer-causing virus.

A new notice on the journal’s website says the article has been permanently withdrawn because of “serious concerns” about its scientific soundness and claims in it that are unjustified.

“The paper … has a seemingly excessive number of gross errors in both methodology and analysis,” said a scathing critique by one of three unnamed reviewers, described by the editor as international experts.

But Yehuda Shoenfeld of Tel-Aviv University, the lead author who is known for research questioning the safety of vaccines, reacted angrily to the latest development.

He accusing the journal’s editor – Dr. Gregory Poland, a Mayo Clinic scientist — of having a conflict of interest because of work he has done for Merck, Gardasil’s manufacturer.

“This reflects an unusually unorthodox and unprofessional conduct from the journal and seems to be part of a pharmaceutical industry push-back to any critique of the Gardasil vaccine,” he wrote in a letter to Poland.

‘To simply retract a paper which reports a result that one does not like makes a mockery of the whole review process’

Poland has disclosed that he is chairman of the safety-evaluation committee for Merck’s investigational vaccine trials, and does consulting for the company.

Shoenfeld’s study was sponsored by the Dwoskin Foundation, a U.S. charity that mostly funds research on purported vaccine safety problems.

Poland said by email he would not comment on the episode, but the conflict-of-interest charge was “without basis,” given that the paper was killed after a review by external experts.

Large studies of recipients worldwide – including one published this month on 200,000 Alberta girls who got the shots — have found no sign of serious safety problems. Infectious-disease, public-health and oncology doctors and scientists are virtually unanimous in supporting the product.

The two University of British Columbia researchers who contributed to the HPV paper — Christopher Shaw of UBC’s ophthalmology department and post-doctoral fellow Lucija Tomljenovic — are well known for work that has linked vaccines to neurological problems.

Shaw said the second round of reviews of the paper contained some valid points that the authors could have addressed if given a chance, and some “trivial” criticisms. None should have doomed the study, he said.

“It is pretty hard to ignore the subject of the article (Gardasil) and Dr. Poland’s ties to Merck,” he said Tuesday.

But his research, which is also heavily backed by Dwoskin, has come under question before, with the World Health Organization and a U.S. Centers for Disease Control committee publishing tough critiques.

The UBC pair and their Israeli colleagues are scientific outliers, producing questionable research that can needlessly scare parents, said Dr. Monika Naus, medical director of the B.C. Centre for Disease Control’s immunization programs.

“It’s one thing when a member of the public stands up on a soap box,” she said. “(But) this is irresponsible science by scientists. These are people who have PhDs behind their names … It causes fear.”

• Email:

(and I have highlighted in red some of the information available on Wikipedia. – Gerda)


From Wikipedia, the free encyclopedia

See also: HPV vaccine


Gardasil vaccine and box new.jpg

Vaccine description

Target disease

human papillomavirus (Types 16, 18, 6, and 11)


Protein subunit

Clinical data






  • US: B (No risk in non-human studies)

Routes of

Intramuscular injection

Legal status

Legal status


ATC code

J07BM01 (WHO)



 Yes (what is this?)  (verify)

Gardasil, also known as Gardisil or Silgard or recombinant human papillomavirus vaccine [types 6, 11, 16, 18],[1][2] is a vaccine for use in the prevention of certain strains of human papillomavirus (HPV),[3] specifically HPV types 6, 11, 16 and 18.[4][5] HPV types 16 and 18 cause an estimated 70% of cervical cancers,[6][7] and are responsible for most HPV-induced anal,[8] vulvarvaginal,[9] and penile cancer cases. HPV types 6 and 11 cause an estimated 90% of genital warts cases. Though it does not treat existing infection, vaccination is still recommended for HPV positive individuals, as it may protect against one or more different strains of the disease.[10] The HPV strains that Gardasil protects against are sexually transmitted. It was approved in the US on June 8, 2006 by the U.S. Food and Drug Administration (FDA). In 2008, Gardasil was approved in 41 of U.S. states.[11] The Gardasil vaccine has also been approved in 120 other countries.[12] The FDA recommends vaccination before adolescence and potential sexual activity.[4][13][14]

In December 2014, the FDA approved a nine-valent Gardasil-based vaccine, Gardasil 9, to protect against infection with the strains covered by the first generation of Gardasil as well as five other HPV strains responsible for 20% of cervical cancers (HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58).[15]



Medical uses[edit]

See also: HPV vaccine § Prevalence of genital HPV

Gardasil is a prophylactic HPV vaccine, meaning that it is designed to prevent HPV infections. For maximum effect, it is recommended that girls receive the vaccine prior to becoming sexually active. However, women who were already infected with one or more of the four HPV types targeted by the vaccine (6, 11, 16, or 18) were protected from clinical disease caused by the remaining HPV types in the vaccine.

Since Gardasil will not block infection with all of the HPV types that can cause cervical cancer, the vaccine should not be considered a substitute for routine pap smears.

Fewer HPV infections mean fewer complications from the virus and less time and money spent on the detection, work-up, and treatment of cervical cancer and its precursor, cervical dysplasia. It prevents infertility caused by cervical biopsies and reduces the severe respiratory problems of children who are infected by HPV from their mothers.

In addition, protection against HPV 6 and HPV 11 is expected to eliminate 90% of the cases of genital warts. Gardasil also protects against vulvar and vaginal cancers caused by HPV types 16 and 18.[9]

In December 2010, Gardasil was approved by the FDA for prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years.[16][17]

HPV infections, especially HPV 16, contribute to some head and neck cancer (HPV is found in an estimated 26-35% of head and neck squamous cell carcinoma).[18][19] In principle, HPV vaccines may help reduce incidence of such cancers caused by HPV, but this has not been demonstrated.[20]

Merck was denied FDA approval to market Gardasil to women aged 27 to 45. Although it was found to be safe and effective in the prevention of genital warts, it was not effective in the prevention of cervical cancer in that age group.[21] This is because HPV rates rise quickly during teenage years and early twenties, but the chances decrease as people reach ages past their early twenties.[22]


An alternative vaccine known as Cervarix is manufactured by GlaxoSmithKline.[23] It protects against two oncogenic strains of HPV, 16 and 18.

The National Cancer Institute says, “Gardasil and Cervarix have been shown to provide protection against persistent cervical HPV 16/18 infections for up to 8 years, which is the maximum time of research follow-up thus far…HPV vaccination has also been found to prevent nearly 100 percent of the precancerous cervical cell changes that would have been caused by HPV 16/18. The data so far show duration of protection for up to 6.4 years with Cervarix and for up to 5 years for Gardasil—in women who were not infected with HPV at the time of vaccination.”[24]

Gardasil has been shown to be partially effective (approximately 38%) in preventing cervical cancer caused by ten other high-risk HPV types.[25]

Antibody levels at month 3 (1 month postdose 2) are substantially higher than at month 24 (18 months postdose 3), suggesting that protection is achieved by month 3 and perhaps earlier.[13][26]This does not imply that the third dose can be skipped.[citation needed] One study has shown that Cervarix may be effective with fewer than three doses.[27] Following further studies, in April 2014, the World Health Organization recommended that countries offer the vaccine in a two dose schedule to girls aged under 15, with each dose at least six months apart.[28] The United Kingdom, Switzerland, Mexico and Quebec are among the few countries or territories to have implemented this as at June 2015.


Gardasil is also effective in males, providing protection against genital wartsanal cancer, and some potentially precancerous lesions caused by some HPV types.[5][17][29][30] An ongoing study of 4,065 males demonstrated the efficacy of Gardasil in males who did not have HPV infection prior to vaccination. The vaccination is expected to protect against penile cancer and anal cancercaused by included HPV types, and research in this area is ongoing.[8] Gardasil vaccine has been shown to significantly decrease the risk of young men contracting genital warts.[31] In the United States the U.S. Food and Drug Administration (FDA) approved administration of the vaccine to males between ages 9 and 26 in October 2009.[32][33][34] In the UK, HPV vaccines are licensed for males aged 9 to 15 and for females aged 9 to 26.[35]

Men who have sex with men (MSM) are particularly at risk for conditions associated with HPV types 6, 11, 16, and 18; diseases and cancers that have a higher incidence among MSM include anal intraepithelial neoplasias, anal cancers, and genital warts. Type 16 is also associated with oropharyngeal squamous-cell carcinoma, a form of throat cancer.[36] A 2005 study in San Francisco found that 95% of HIV-infected gay men also had anal HPV infection, of which 50% had precancerous HPV-caused lesions.[37]


Gardasil is given in three injections over six months. The second injection is two months after the first, and the third injection is six months after the first shot was administered.[4][13] Alternatively, in some countries it is given as two injections with at least six months between them, for individuals aged 9 years up to and including 13 years. [38]

Adverse effects[edit]

As of April 2014, more than 170 million doses of Gardasil had been distributed worldwide.[39] The vaccine was tested in thousands of females (ages 9 to 26).[40] The Food and Drug Administration(FDA) and the Centers for Disease Control and Prevention (CDC) consider the vaccine to be safe. It does not contain mercurythiomersal, live viruses or dead viruses, but virus-like particles, which cannot reproduce in the human body.[40]

Publications of FDA and the CDC state that the vaccine has mostly minor side effects, such as soreness around the injection area.[40] Fainting is more common among adolescents receiving the Gardasil vaccine than in other kinds of vaccinations. Patients should remain seated for 15 minutes after they receive the HPV vaccine.[41] There have been reports that the shot is more painful than other common vaccines, and the manufacturer Merck partly attributes this to the virus-like particles within the vaccine.[42] General side effects of the shot may include joint and muscle pain, fatigue, physical weakness and general malaise.[41][43]

An update on adverse events was published by the Journal of the American Medical Association and looked at data from the Vaccine Adverse Event Reporting System (VAERS), covering 12,424 reported adverse events after about 23 million doses of vaccine between June 2006 and December 2008.[44][45] Most adverse effects were minor and not greater than background rates compared with other vaccines, the exception being higher rates for syncope and thromboembolic events.[45] Venous thromboembolic events were noted in 56 reports at a rate of 0.2 cases per 100,000 doses distributed and included 19 cases of pulmonary embolism, four of which were fatal.[45] Overall, 772 events (6.2% of the total number of adverse events but only 0.003% of the total number of doses) were described as serious and included 32 reported deaths (1 per 1,000,000 doses).[45]

Other adverse events include local site reactions (7.5 cases per 100,000 doses distributed), headaches (4.1 cases per 100,000 doses distributed), hypersensitivity reactions (3.1 cases per 100,000 doses distributed), and urticaria (hives) (2.6 cases per 100,000 doses distributed).[45] A Kaiser Permanente study tracking 190,000 girls and women post-vaccination for two years found that rates of the autoimmune disorders lupusrheumatoid arthritisjuvenile rheumatoid arthritisidiopathic thrombocytopenic purpura (ITP), hemolytic anemiamultiple sclerosisthyroiditis and type 1 diabetes mellitus in vaccinated populations were the same as in unvaccinated populations.[46][47]

The FDA and the CDC said that with millions of vaccinations “by chance alone some serious adverse effects and deaths” will occur in the time period following vaccination, but they have nothing to do with the vaccine.[48] More than twenty women who received the Gardasil vaccine have died, but these deaths have not been causally connected to the shot.[48] Where information has been available, the cause of death was explained by other factors.[49][50] Likewise, a small number of cases of Guillain-Barré Syndrome (GBS) have been reported following vaccination with Gardasil, though there is no evidence linking GBS to the vaccine.[14][44][51] It is unknown why a person develops GBS, or what initiates the disease.[52]

The FDA and the CDC monitor events to see if there are patterns, or more serious events than would be expected from chance alone.[49] The majority (68%) of side effects data were reported by the manufacturer, but in about 90% of the manufacturer reported events, no follow-up information was given that would be useful to investigate the event further.[45] In February 2009, the Spanish ministry of health suspended use of one batch of Gardasil after health authorities in the Valencia region reported that two girls had become ill after receiving the injection. Merck has stated that there was no evidence Gardasil was responsible for the two illnesses.[53]



The HPV major capsid protein, L1, can spontaneously self-assemble into virus-like particles (VLPs) that resemble authentic HPV virions. Gardasil contains recombinant VLPs assembled from the L1 proteins of HPV types 6, 11, 16 and 18. Since VLPs lack the viral DNA, they cannot induce cancer. They do, however, trigger an antibody response that protects vaccine recipients from becoming infected with the HPV types represented in the vaccine. The L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae and self-assembled into VLPs.[54]

Public health[edit]

Main article: HPV Vaccine

The National Cancer Institute writes:

Widespread vaccination has the potential to reduce cervical cancer deaths around the world by as much as two-thirds, if all women were to take the vaccine and if protection turns out to be long-term. In addition, the vaccines can reduce the need for medical care, biopsies, and invasive procedures associated with the follow-up from abnormal Pap tests, thus helping to reduce health care costs and anxieties related to abnormal Pap tests and follow-up procedures.[24]

Long-term impact and cost-effectiveness[edit]

Whether the effects are temporary or lifelong, widespread vaccination could have a substantial public health impact. 270,000 women died of cervical cancer worldwide in 2002.[55] Acting FDA Administrator Andrew von Eschenbach said the vaccine will have “a dramatic effect” on the health of women around the world.[56] Even in the United States, where screening programs are routine, the National Cancer Institute estimated that 9,700 women would develop cervical cancer in 2006, and 3,700 would die.[57]

Merck and CSL Limited are expected to market Gardasil as a cancer vaccine, rather than an STD vaccine. It remains unclear how widespread the use of the three-shot series will be, in part because of its $525 list price ($175 each for three shots).[58]

Studies using different pharmacoeconomic models predict that vaccinating young women with Gardasil in combination with screening programs may be more cost effective than screening alone.[59]These results have been important in decisions by many countries to start vaccination programs.[60] For example, the Canadian government approved $300 million to buy the HPV vaccine in 2008 after deciding from studies that the vaccine would be cost-effective especially by immunizing young women.[61] Marc Steben, an investigator for the vaccine, wrote that the financial burden of HPV related cancers on the Canadian people was already $300 million per year in 2005, so the vaccine could reduce this burden and be cost-effective.[62]

Since penile and anal cancers are much less common than cervical cancer, HPV vaccination of young men is likely to be much less cost-effective than for young women.[48]

The August 2009 issue of the Journal of the American Medical Association had an article reiterating the safety of Gardasil[44] and another questioning the way it was presented to doctors and parents.

The new vaccine against 4 types of human papillomavirus (HPV), Gardasil, like other immunizations appears to be a cost-effective intervention with the potential to enhance both adolescent health and the quality of their adult lives. However, the messages and the methods by which the vaccine was marketed present important challenges to physician practice and medical professionalism. By making the vaccine’s target disease cervical cancer, the sexual transmission of HPV was minimized, the threat of cervical cancer to adolescents was maximized, and the subpopulations most at risk practically ignored. The vaccine manufacturer also provided educational grants to professional medical associations (PMAs) concerned with adolescent and women’s health and oncology. The funding encouraged many PMAs to create educational programs and product-specific speakers’ bureaus to promote vaccine use. However, much of the material did not address the full complexity of the issues surrounding the vaccine and did not provide balanced recommendations on risks and benefits. As important and appropriate as it is for PMAs to advocate for vaccination as a public good, their recommendations must be consistent with appropriate and cost-effective use.[63]

According to the CDC, as of 2012, use of the HPV vaccine had cut rates of infection with HPV-6, -11, -16 and -18 in half in American teenagers (from 11.5% to 4.3%) and by one third in American women in their early twenties (from 18.5% to 12.1%).[64]


The research findings that pioneered the development of the vaccine began in 1991 by investigators Jian Zhou and Ian Frazer in The University of Queensland, Australia . Researchers at UQfound a way to form non-infectious virus-like particles (VLP), which could also strongly activate the immune system. Subsequently, the final form of the vaccine was developed in parallel, by researchers at Georgetown University Medical Center, the University of Rochester, the University of Queensland in Australia, and the U.S. National Cancer Institute.[65]

Clinical trials[edit]

Merck & Co. conducted a Phase III study named Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE II). This clinical trial was a randomized double-blind study with one controlled placebo group and one vaccination group. Over 12,000 women aged 16–26 from thirteen countries participated in the study. Each woman was injected with either Gardasil or a placebo on day 1, month 2, and month 6. In total, 6,082 women were given Gardasil and 6,075 received the placebo.[66] Subjects in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV-16 or HPV-18 than did those in the placebo group.[66] On February 27, 2007, the independent Data and Safety Monitoring Board recommended the clinical trials be terminated on ethical grounds, so that young women on placebo could receive Gardasil.[67] The safety and efficacy of the vaccine was also demonstrated in a clinical trial including over one thousand 9- to 15-year-old girls.[68]

Society and culture[edit]

United States[edit]

The governor of Texas, Rick Perry, issued an executive order adding Gardasil to the state’s required vaccination list, which was later overturned by the Texas legislature. Perry has also allowed parents to opt out of the program more easily. Through lobbying efforts, Merck has suggested that governments make vaccination with Gardasil mandatory for school attendance, which has upset some conservative groups and libertarian groups.[56][69][70] Conservative groups, including the Family Research Council (FRC), have expressed fear that vaccination with Gardasil might give girls a false sense of security regarding sex and lead to promiscuity,[56][70][71][72] but no evidence exists to suggest that girls who were vaccinated went on to engage in more sexual activity than unvaccinated girls.[73] Perry’s decision was later criticized on September 12, 2011 by fellow presidential candidates Ron Paul and Michele Bachmann during the Republican Party presidential debate as being an overreach of state power in a decision properly left to parents.[74]


In June 2013, the Japanese government issued a notice that “cervical cancer vaccinations should no longer be recommended for girls aged 12 to 16” while an investigation is conducted into certain adverse events including pain and numbness in 38 girls.[75] The vaccines sold in Japan are Cervarix, made by GlaxoSmithKlein PLC of Britain, and Gardasil, made by Merck Sharp & Dohme. An estimated 3.28 million people have received the vaccination; 1,968 cases of possible side effects have been reported.[76]